News | G茅nome Qu茅bec invests up to $500,000 to boost RNA therapeutics innovation in Quebec
G茅nome Qu茅bec invests up to $500,000 to boost RNA therapeutics innovation in Quebec
G茅nome Qu茅bec, a private, non-profit organization dedicated to advancing genomics research and innovation in Quebec, is investing up to $500,000 in 平特五不中鈥檚 D2R Initiative. This investment will advance the commercialization of innovative genomic technologies in Quebec through 顿2搁鈥檚 Commercialization Priming funding program.
顿2搁鈥檚 Commercialization Priming funding program is designed to attract industry partners and investors while advancing genomic-based RNA therapeutic research. It provides short-term financial support to researchers to help test and validate the commercial potential of concepts, technologies, or inventions aligned with D2R priority areas: rare diseases, infectious diseases and oncology.
The Commercialization Priming program is part of a suite of D2R funding programs that support interdisciplinary research in line with 顿2搁鈥檚 vision of delivering revolutionary genomic-based RNA therapies for all. D2R is supported by the Canada First Research Excellence Fund, as well as additional support from the Quebec Government and other philanthropic and industry partners.
鈥溒教匚宀恢锈�檚 D2R initiative is contributing significantly to advancing transformative genomics-based RNA research in the province,鈥� said Dominique B茅rub茅, Vice-President, Research and Innovation at 平特五不中. 鈥淭his investment from G茅nome Qu茅bec provides the vital support researchers and industry partners need for the development and biomanufacturing of novel therapeutics. We look forward to the innovations that will result from this collaboration.鈥�
鈥淲e are thrilled to partner with D2R to accelerate genomics research applications and foster innovation in Quebec. By supporting 顿2搁鈥檚 Commercialization Priming funding program, we aim to de-risk transformative genomic-based RNA therapeutics and capitalize on the province's strengths in genomics.鈥� St茅phanie Lord-Fontaine, Vice President, Scientific Affairs, G茅nome Qu茅bec.
G茅nome Qu茅bec鈥檚 investment to D2R shows their commitment to enhancing Quebec鈥檚 position as a leader in RNA-based therapies. This commitment is further demonstrated through their active involvement in AReNA, a new RNA hub recently announced by the government of Quebec, which brings together key players in life sciences, including D2R and G茅nome Qu茅bec, to bring Quebec to the forefront of innovation in RNA therapies.
For more information about D2R and its Commercialization Priming funding program, please visit the D2R website.
听
#
About D2R: DNA to RNA, An inclusive Canadian approach to genomic-based RNA therapeutics
平特五不中's groundbreaking research initiative, DNA to RNA (D2R), is committed to advancing genomic-based RNA therapies for those affected by infectious diseases, rare diseases or cancer. With a transformative $165 million investment from the Canada First Research Excellence Fund, alongside support from the Quebec Government, philanthropic donors, and industry partners, D2R will develop revolutionary RNA therapeutics.
For more details, visit www.mcgill.ca/dna-to-rna/
About G茅nome Qu茅bec:
G茅nome Qu茅bec鈥檚 mission is to catalyze the development and excellence of genomics research and promote its integration and democratization. It is a pillar of the Qu茅bec bioeconomy and contributes to Qu茅bec鈥檚 influence and its social and sustainable development. The funds invested by G茅nome Qu茅bec are provided by the minist猫re de l'脡conomie, de l'Innovation et de l鈥櫭塶ergie du Qu茅bec (MEIE), the government of Canada, through Genome Canada, and private partners.
To learn more, visit .
